Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT02148159
Collaborator
(none)
45
1
2
19
2.4

Study Details

Study Description

Brief Summary

Patients with cancer often experience appetite loss and weight loss unintentionally. Rapid weight loss negatively impact on physical functioning, quality of life, and overall survival. Patients will be randomly assigned into two groups. An intervention with acupuncture may slow down or stop the progression of cancer-related anorexia and weight loss.

Condition or Disease Intervention/Treatment Phase
  • Device: Cachexia Acupuncture-A (Peace Classic Needles® )
  • Device: General Acupuncture-B (Peace Classic Needles®)
N/A

Detailed Description

The purpose of this research study is to investigate if acupuncture helps to improve appetite and slow down unintentional weight loss. The participants will be randomly divided into two groups and receive 8 sessions of acupuncture (two groups will receive different acupuncture points) for 8 weeks. During the study period, participants will be asked various questions about appetite, physical functioning, cancer-related symptoms and quality of life to understand changes related to body weight, as well as blood samples. The research team members will collect data regarding changes in appetite, body weight, body composition, and physical functioning.

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients With Cachexia
Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
May 1, 2016
Actual Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cachexia Acupuncture-A

Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period. Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture

Device: Cachexia Acupuncture-A (Peace Classic Needles® )
Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
Other Names:
  • Acu-Market
  • Mechanism based acupuncture
  • Sham Comparator: General Acupuncture-B

    General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted. Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture

    Device: General Acupuncture-B (Peace Classic Needles®)
    Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
    Other Names:
  • Acu-Market
  • General acupuncture
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage weight change over 8 weeks between two arms [up to 8 weeks]

      Weight will be measured each visit (pounds).

    Secondary Outcome Measures

    1. Appetite change between two arms [up to 8 weeks]

      Three different short survey forms will be used to measure appetite change. Visual analogue scale (0 indicates no appetite and 10 is the best appetite). Simplified Nutritional Appetite Questionnaire score (min-max: 4-20 and the higher the better appetite) Patient Generated Subjective Global Assessment: 0-1, no intervention is needed. 9 or higher score indicates critical intervention.

    2. physical functioning [up to 8 weeks]

      survey form (min-max: 0-100, increment by 10%- 100% indicates full functioning).

    3. body composition [up to 8 weeks]

      Small, non-invasive device (bioelectrical impedance analysis) like a miniature version of EKG will measure changes in body composition (numeric scale).

    Other Outcome Measures

    1. Quality of life between two arms [up to 8 weeks]

      Survey format includes the 27 items (5 points scale: 0 means 'not at all' and 4 means 'very much") .

    2. biomarkers [weeks 1, 4 and 8 (three measurements)]

      Small amounts of blood will be drawn.

    3. symptom experience [up to 8 weeks]

      Survey format: 13 areas related to the symptom experience and patient's concerns will be assessed (4 points scale; 0 means 'not at all' and 3 means 'very much').

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 21 year or older

    • medical diagnosis of gastrointestinal cancer (for example, gastric, biliary, or colorectal)

    • experienced weight loss of at least 5% over the last 6 months

    • ability to communicate in English

    • ability to follow the research protocol

    Exclusion Criteria:
    • plan to have surgical procedures at the time of recruitment

    • receive radiation therapy alone or in addition to chemotherapy during the study period

    • undergo surgery during the study or in the months prior to the study

    • no plan to have chemotherapy after the surgery

    • any comorbidities that may affect the interpretation of study findings

    • open burn sites or infected wounds

    • esophageal cancer or pancreatic cancer

    • life expectancy of less than 6 months as assessed by attending physician

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Florida Clinical Research Center (CRC) Gainesville Florida United States 32610-0219

    Sponsors and Collaborators

    • University of Florida

    Investigators

    • Principal Investigator: Saunjoo Yoon, PhD, University of Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Florida
    ClinicalTrials.gov Identifier:
    NCT02148159
    Other Study ID Numbers:
    • IRB201400340
    • OCR14647
    First Posted:
    May 28, 2014
    Last Update Posted:
    Jan 17, 2019
    Last Verified:
    Jan 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 17, 2019